News
UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...
While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.
Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.
SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.
1d
Zacks Small Cap Research on MSNSNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment ...
Linvoseltamab gains FDA approval as an effective off-the-shelf therapy for relapsed multiple myeloma, showcasing impressive response rates and safety profiles.
Stroke often results in persistent gait impairments, limiting mobility and reducing quality of life. This study evaluated FAST walk, a novel electromyography-triggered system that combines ...
Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...
The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results